Carbapenem-Resistant Enterobacteriaceae: Epidemiology and Prevention | Zendy

Neil Gupta | Zendy; Brandi Limbago | Zendy; Jean B. Patel | Zendy; Alexander J. Kallen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Carbapenem-Resistant Enterobacteriaceae: Epidemiology and Prevention

Author(s) -

Neil Gupta,

Brandi Limbago,

Jean B. Patel,

Alexander J. Kallen

Publication year - 2011

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cir202

Subject(s) - carbapenem resistant enterobacteriaceae , enterobacteriaceae , klebsiella pneumoniae , epidemiology , medicine , public health , environmental health , molecular epidemiology , microbiology and biotechnology , biology , genotype , gene , escherichia coli , genetics , pathology

Over the past 10 years, dissemination of Klebsiella pneumoniae carbapenemase (KPC) has led to an increase in the prevalence of carbapenem-resistant Enterobacteriaceae (CRE) in the United States. Infections caused by CRE have limited treatment options and have been associated with high mortality rates. In the previous year, other carbapenemase subtypes, including New Delhi metallo-β-lactamase, have been identified among Enterobacteriaceae in the United States. Like KPC, these enzymes are frequently found on mobile genetic elements and have the potential to spread widely. As a result, preventing both CRE transmission and CRE infections have become important public health objectives. This review describes the current epidemiology of CRE in the United States and highlights important prevention strategies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research